Clinical trials: Retinoschisis

X-linked Retinoschisis

Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS)

• Completed
• Age: 6 years and older
• Phase 1/2
• Results posted

This study will evaluate the safety and efficacy of a recombinant adeno-associated virus vector expressing retinoschisin (rAAV2tYF-CB-hRS1) in patients with X-linked retinoschisis.

Trial name

NCT02416622

Testing

rAAV2tYF-CB-hRS1

Where

9 sites in United States

Volunteers

27 people

Sponsor

Beacon Therapeutics